RecruitingNCT07390240

The Effect of Monoallelic Variants in the ALPL Gene on the Natural Course of Hypophosphatasia in Russia

The Effect of Monoallelic Variants in the ALPL Gene on the Natural Course of Hypophosphatasia (HPP) in Children and Adults in Russia

Sponsor

AstraZeneca

Enrollment

55 participants

Start Date

Dec 29, 2025

Study Type

OBSERVATIONAL

Conditions

The effect of monoallelic variants in the ALPL gene on the natural course of hypophosphatasia (HPP) in children and adults in Russia (ATLANTIS)

Age ≥4 to <18 years, or ≥18 years at the time of enrollment;
Signed ICF for patients ≥18 years, or legal representatives (parents) of patients aged ≥4 to <18 years;
Written informed assent (for patients aged ≥14 to <18 years only);
No history of HPP treatment with enzyme-replacement therapy;
Diagnosis of HPP confirmed by:
reduced alkaline phosphatase (ALP) activity relative to age- and sex-specific reference ranges, confirmed by at least two separate measurements, AND
the identification of a monoallelic pathogenic, likely pathogenic, or variant of uncertain significance in the ALPL gene on genetic testing.

Confirmed conditions presenting with clinical features overlapping with HPP, including but not limited to: cerebral palsy, Duchenne muscular dystrophy, limb-girdle muscular dystrophy (Erb-Roth dystrophy), acquired secondary myopathies of various etiologies;
Сurrent participation in any clinical study (patients participating in other non interventional studies may be included);
Homozygous or compound heterozygous mutation in the ALPL gene
In the opinion of the investigator, the patient is not able to return for follow-up visits or obtain required follow-up studies.
Pregnant and breastfeeding women.

Interested in this trial?

Get notified about updates and connect with the research team.